Frederique Tesson

Dr. Frederique Tesson

Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2010 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
PGPallavi Gupta
Pallavi Gupta
ZBZofia T. Bilińska
Zofia T. Bilińska
NSNicolas Sylvius
Nicolas Sylvius
EBEmilie Boudreau
Emilie Boudreau
JVJohn P. Veinot
John P. Veinot
Frederique TessonFrederique Tesson
Frederique Tesson

29 August 2014 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Frederique TessonFrederique Tesson
Frederique Tesson
MSMichal Saj
Michal Saj
MUMusfira Mohamed Uvaize
Musfira Mohamed Uvaize
HNHannah Nicolas
Hannah Nicolas
RPRafal Ploski
Rafal Ploski
ZBZofia T. Bilińska
Zofia T. Bilińska
Dilated cardiomyopathy (DCM) is one of the leading causes of heart failure and heart transplant. Mutations in 60 genes have been associated with DCM. Approximately 6% of all DCM cases are caused by mutations in the lamin A/C gene (LMNA). LMNA codes for type-V intermediate filaments that support the structure of the nuclear membrane and are involved in chromatin structure and gene expression. Most LMNA mutations result in striated muscle diseases while the rest affects the adipose tissue, peripheral nervous system, multiple tissues or lead to progeroid syndromes/overlapping syndromes. Patients with LMNA mutations exhibit a variety of cellular and physiological phenotypes. This paper explores the current phenotypes observed in LMNA-caused DCM, the results and implications of the cellular and animal models of DCM and the prevailing theories on the pathogenesis of laminopathies. Dilated cardiomyopathy (DCM) is one of the leading causes of heart failure and heart transplant. Mutations in 60 genes have been associated with DCM. Approximately 6% of all DCM cases are caused by mutations in the lamin A/C gene (LMNA). LMNA codes for type-V intermediate filaments that support the structure of the nuclear membrane and are involved in chromatin structure and gene expression. Most LMNA mutations result in striated muscle diseases while the rest affects the adipose tissue, peripheral nervous system, multiple tissues or lead to progeroid syndromes/overlapping syndromes. Patients with LMNA mutations exhibit a variety of cellular and physiological phenotypes. This paper explores the current phenotypes observed in LMNA-caused DCM, the results and implications of the cellular and animal models of DCM and the prevailing theories on the pathogenesis of laminopathies.

21 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ÉBÉmilie Boudreau
Émilie Boudreau
SLSarah Labib
Sarah Labib
ABAnne Bertrand
Anne Bertrand
VDValérie Decostre
Valérie Decostre
PBPierrette M Bolongo
Pierrette M Bolongo
Frederique TessonFrederique Tesson
Frederique Tesson
A-type lamins A and C are nuclear intermediate filament proteins in which mutations have been implicated in multiple disease phenotypes commonly known as laminopathies. A few studies have implicated sumoylation in the regulation of A-type lamins. Sumoylation is a post-translational protein modification that regulates a wide range of cellular processes through the attachment of small ubiquitin-related modifier (sumo) to various substrates. Here we showed that laminopathy mutants result in the mislocalization of sumo1 both in vitro (C2C12 cells overexpressing mutant lamins A and C) and in vivo (primary myoblasts and myopathic muscle tissue from the LmnaH222P/H222P mouse model). In C2C12 cells, we showed that the trapping of sumo1 in p.Asp192Gly, p.Gln353Lys, and p.Arg386Lys aggregates of lamin A/C correlated with an increased steady-state level of sumoylation. However, lamin A and C did not appear to be modified by sumo1. Our results suggest that mutant lamin A/C alters the dynamics of sumo1 and thus misregulation of sumoylation may be contributing to disease progression in laminopathies.

1 June 2018 in Metabolism
Verified
Journal Article
Closed access
ARAbishankari Rajkumar
Abishankari Rajkumar
ALAwa Liaghati
Awa Liaghati
JCJessica Chan
Jessica Chan
GLGilles Lamothe
Gilles Lamothe
RDRobert Dent
Robert Dent
Frederique TessonFrederique Tesson
Frederique Tesson

Verified
Journal Article
Open access
PDF file
PCPrzemysław Chmielewski
Przemysław Chmielewski
EMEwa Michalak
Ewa Michalak
IKIlona Kowalik
Ilona Kowalik
MFMaria Franaszczyk
Maria Franaszczyk
MSMalgorzata Sobieszczanska-Malek
Malgorzata Sobieszczanska-Malek
ZBZofia T. Bilińska
Zofia T. Bilińska
Mutations in the lamin A/C gene are variably phenotypically expressed; however, it is unclear whether circulating cardiac biomarkers are helpful in the detection and risk assessment of cardiolaminopathies. We sought to assess (1) clinical characteristics including serum biomarkers: high sensitivity troponin T (hsTnT) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) in clinically stable cardiolaminopathy patients, and (2) outcome among pathogenic/likely pathogenic lamin A/C gene (LMNA) mutation carriers. Our single-centre cohort included 53 patients from 21 families. Clinical, laboratory, follow-up data were analysed. Median follow-up was 1522 days. The earliest abnormality, emerging in the second and third decades of life, was elevated hsTnT (in 12% and in 27% of patients, respectively), followed by the presence of atrioventricular block, heart failure, and malignant ventricular arrhythmia (MVA). In patients with missense vs. other mutations, we found no difference in MVA occurrence and, surprisingly, worse transplant-free survival. Increased levels of both hsTnT and NT-proBNP were strongly associated with MVA occurrence (HR > 13, p ≤ 0.02 in both) in univariable analysis. In multivariable analysis, NT-proBNP level > 150 pg/mL was the only independent indicator of MVA. We conclude that assessment of circulating cardiac biomarkers may help in the detection and risk assessment of cardiolaminopathies.

1 March 2007 in Applied Physiology, Nutrition, and Metabolism
Verified
Journal Article
Closed access
KAKristi B. Adamo
Kristi B. Adamo
Frederique TessonFrederique Tesson
Frederique Tesson
Obesity, whose prevalence is continually rising, is one of the world’s greatest health care burdens. This multifactorial condition is associated with many obesity-related conditions, such as type 2 diabetes, dyslipidemia, and cardiovascular disease. Weight loss is a significant challenge facing those wishing to reduce their disease risk. Of course, like obesity itself, weight loss is a complex phenomenon dependent on many environmental and genetic influences, and thus individual responses to weight loss interventions are incredibly variable. Currently, there are 3 major interventions used to reduce weight: diet, exercise, and pharmacotherapy. The findings from studies examining gene–diet (nutrigenetic), gene–exercise (actigenetic), and gene–pharmaceutical (pharmacogenetic) interactions, although not clinically applicable at this time, are gaining awareness. This review article summarizes the current evidence to support the contribution of DNA sequence variation in genes related to energy balance (expenditure and intake) in the response to weight loss intervention. There is no doubt that replication using more rigorous study designs that include the study of interactions between multiple genes and interventions is required to move towards the development of genotype-specific weight loss treatment strategies.